Using a cell line breast cancer progression system to identify biomarker candidates

Journal of Proteomics

Volumn 96, Issue , 2014, Pages 173-183

  Yen, Ten Yang ^a   Haste, Nicole ^a   Timpe, Leslie C ^a   Litsakos Cheung, Christina ^a   Yen, Roger ^a   Macher, Bruce A ^a  

^a SAN FRANCISCO STATE UNIVERSITY   (United States)

Author keywords

Breast cancer; Differential expression; Glycoproteomics; Label free quantitation; Non malignant vs. malignant; Spectral counts

Indexed keywords

COLLAGEN; COLLAGEN ALPHA1 CHAIN; GLYCOPROTEIN; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER GROWTH; CELL LYSATE; CELL MEMBRANE; CELL SURFACE; COMPARATIVE STUDY; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; LIQUID CHROMATOGRAPHY; LIQUID CHROMATOGRAPHY TANDEM MASS SPECTROMETRY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN SECRETION; PROTEOMICS; TANDEM MASS SPECTROMETRY;

BREAST CANCER; DIFFERENTIAL EXPRESSION; GLYCOPROTEOMICS; LABEL-FREE QUANTITATION; NON-MALIGNANT VS. MALIGNANT; SPECTRAL COUNTS;

BREAST NEOPLASMS; CELL LINE, TUMOR; COLLAGEN TYPE XII; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASM PROTEINS; TUMOR MARKERS, BIOLOGICAL;

EID: 84889576313     PISSN: 18743919     EISSN: 18767737     Source Type: Journal    
DOI: 10.1016/j.jprot.2013.11.006     Document Type: Article

References (43)

1. Hanahan D., Weinberg Robert A. Hallmarks of cancer: the next generation. Cell 2011, 144(5):646-674.
2. Basolo F., Elliott J., Tait L., Chen X.Q., Maloney T., Russo I.H., et al. Transformation of human breast epithelial cells by c-Ha-ras oncogene. Mol Carcinog 1991, 4(1):25-35.
3. Santner S., Dawson P., Tait L., Soule H., Eliason J., Mohamed A., et al. Malignant MCF10CA1 cell lines derived from premalignant human breast epithelial MCF10AT cells. Breast Cancer Res Treat 2001, 65(2):101-110.
4. Kalluri R., Weinberg R.A. The basics of epithelial-mesenchymal transition. J Clin Invest 2009, 119(6):1420-1428.
5. Kim Y.J., Varki A. Perspectives on the significance of altered glycosylation of glycoproteins in cancer. Glycoconj J 1997, 14(5):569-576.
6. Zou Z., Ibisate M., Zhou Y., Aebersold R., Xia Y., Zhang H. Synthesis and evaluation of superparamagnetic silica particles for extraction of glycopeptides in the microtiter plate format. Anal Chem 2008, 80(4):1228-1234.
7. Berven F.S., Ahmad R., Clauser K.R., Carr S.A. Optimizing performance of glycopeptide capture for plasma proteomics. J Proteome Res 2010, 9(4):1706-1715.
8. Yen T.Y., Macher B.A., McDonald C.A., Alleyne-Chin C., Timpe L.C. Glycoprotein profiles of human breast cells demonstrate a clear clustering of normal/benign versus malignant cell lines and basal versus luminal cell lines. J Proteome Res 2012, 11(2):656-667.
9. 18O-labeling of N-glycosylation sites to improve the identification of gel-separated glycoproteins using peptide mass mapping and database searching. Anal Chem 1999, 71(7):1431-1440.
10. Yen T.-Y., Dutta S.M., Litsakos-Cheung C., Corona A., Timpe L.C., Macher B.A. Overcoming challenges and opening new opportunities in glycoproteomics. Biomol 2013, 3(2):270-286.
11. Perkins D.N., Pappin D.J.C., Creasy D.M., Cottrell J.S. Probability-based protein identification by searching sequence databases using mass spectrometry data. Electrophoresis 1999, 20(18):3551-3567.
12. Craig R., Beavis R.C. A method for reducing the time required to match protein sequences with tandem mass spectra. Rapid Commun Mass Spectrom 2003, 17(20):2310-2316.
13. Nesvizhskii A.I., Keller A., Kolker E., Aebersold R. A statistical model for identifying proteins by tandem mass spectrometry. Anal Chem 2003, 75(17):4646-4658.
14. Keller A., Nesvizhskii A.I., Kolker E., Aebersold R. Empirical statistical model to estimate the accuracy of peptide identifications made by MS/MS and database search. Anal Chem 2002, 74(20):5383-5392.
15. Tusher V.G., Tibshirani R., Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci 2001, 98(9):5116-5121.
16. Saeed A.I., Sharov V., White J., Li J., Liang W., Bhagabati N., et al. TM4: a free, open-source system for microarray data management and analysis. Biotechniques 2003, 34(2):374-378.
17. McDonald C.A., Yang J.Y., Marathe V., Yen T.Y., Macher B.A. Combining results from lectin affinity chromatography and glycocapture approaches substantially improves the coverage of the glycoproteome. Mol Cell Proteomics 2009, 8(2):287-301.
18. Arcinas A., Yen T.Y., Kebebew E., Macher B.A. Cell surface and secreted protein profiles of human thyroid cancer cell lines reveal distinct glycoprotein patterns. J Proteome Res 2009, 8(8):3958-3968.
19. Spahr C.S., Davis M.T., McGinley M.D., Robinson J.H., Bures E.J., Beierle J., et al. Towards defining the urinary proteome using liquid chromatography-tandem mass spectrometry I. Profiling an unfractionated tryptic digest. Proteomics 2001, 1(1):93-107.
20. Wolters D.A., Washburn M.P., Yates J.R. An automated multidimensional protein identification technology for shotgun proteomics. Anal Chem 2001, 73(23):5683-5690.
21. Zhang Y., Wen Z., Washburn M.P., Florens L. Effect of dynamic exclusion duration on spectral count based quantitative proteomics. Anal Chem 2009, 81(15):6317-6326.
22. Liu H., Sadygov R.G., Yates J.R. A model for random sampling and estimation of relative protein abundance in shotgun proteomics. Anal Chem 2004, 76(14):4193-4201.
23. Old W.M., Meyer-Arendt K., Aveline-Wolf L., Pierce K.G., Mendoza A., Sevinsky J.R., et al. Comparison of label-free methods for quantifying human proteins by shotgun proteomics. Mol Cell Proteomics 2005, 4(10):1487-1502.
24. Pavelka N., Fournier M.L., Swanson S.K., Pelizzola M., Ricciardi-Castagnoli P., Florens L., et al. Statistical similarities between transcriptomics and quantitative shotgun proteomics data. Mol Cell Proteomics 2008, 7(4):631-644.
25. Wurtz S.O., Schrohl A.S., Sorensen N.M., Lademann U., Christensen I.J., Mouridsen H., et al. Tissue inhibitor of metalloproteinases-1 in breast cancer. Endocr Relat Cancer 2005, 12(2):215-227.
26. Massot O., Baskevitch P.P., Capony F., Garcia M., Rochefort H. Estradiol increases the production of alpha 1-antichymotrypsin in MCF7 and T47D human breast cancer cell lines. Mol Cell Endocrinol 1985, 42(3):207-214.
27. Kufe D.W. MUC1-C oncoprotein as a target in breast cancer: activation of signaling pathways and therapeutic approaches. Oncogene 2012, 32(9):1073-1081.
28. Tarp M.A., Sorensen A.L., Mandel U., Paulsen H., Burchell J., Taylor-Papadimitriou J., et al. Identification of a novel cancer-specific immunodominant glycopeptide epitope in the MUC1 tandem repeat. Glycobiology 2007, 17(2):197-209.
29. Walsh M.D., Luckie S.M., Cummings M.C., Antalis T.M., McGuckin M.A. Heterogeneity of MUC1 expression by human breast carcinoma cell lines in vivo and in vitro. Breast Cancer Res Treat 1999, 58(3):255-266.
30. Mbeunkui F., Metge B.J., Shevde L.A., Pannell L.K. Identification of differentially secreted biomarkers using LC-MS/MS in isogenic cell lines representing a progression of breast cancer. J Proteome Res 2007, 6(8):2993-3002.
31. Wang Y., Ao X., Vuong H., Konanur M., Miller F.R., Goodison S., et al. Membrane glycoproteins associated with breast tumor cell progression identified by a lectin affinity approach. J Proteome Res 2008, 7(10):4313-4325.
32. Boersema P.J., Geiger T., Wisniewski J.R., Mann M. Quantification of the N-glycosylated secretome by super-SILAC during breast cancer progression and in human blood samples. Mol Cell Proteomics 2013, 12(1):158-171.
33. Lai T.C., Chou H.C., Chen Y.W., Lee T.R., Chan H.T., Shen H.H., et al. Secretomic and proteomic analysis of potential breast cancer markers by two-dimensional differential gel electrophoresis. J Proteome Res 2010, 9(3):1302-1322.
34. van den Berg Y.W., Osanto S., Reitsma P.H., Versteeg H.H. The relationship between tissue factor and cancer progression: insights from bench and bedside. Blood 2012, 119(4):924-932.
35. Ueno T., Toi M., Koike M., Nakamura S., Tominaga T. Tissue factor expression in breast cancer tissues: its correlation with prognosis and plasma concentration. Br J Cancer 2000, 83(2):164-170.
36. Versteeg H.H., Schaffner F., Kerver M., Petersen H.H., Ahamed J., Felding-Habermann B., et al. Inhibition of tissue factor signaling suppresses tumor growth. Blood 2008, 111(1):190-199.
37. Bianchi-Smiraglia A., Paesante S., Bakin A.V. Integrin beta5 contributes to the tumorigenic potential of breast cancer cells through the Src-FAK and MEK-ERK signaling pathways. Oncogene 2012, 32(25):3049-3058.
38. Smollich M., Gotte M., Yip G.W., Yong E.S., Kersting C., Fischgrabe J., et al. On the role of endothelin-converting enzyme-1 (ECE-1) and neprilysin in human breast cancer. Breast Cancer Res Treat 2007, 106(3):361-369.
39. Ishikawa N., Daigo Y., Takano A., Taniwaki M., Kato T., Tanaka S., et al. Characterization of SEZ6L2 cell-surface protein as a novel prognostic marker for lung cancer. Cancer Sci 2006, 97(8):737-745.
40. Schröder C., Witzel I., Müller V., Krenkel S., Wirtz R., Jänicke F., et al. Prognostic value of intercellular adhesion molecule (ICAM)-1 expression in breast cancer. J Cancer Res Clin Oncol 2011, 137(8):1193-1201.
41. Ogawa Y., Hirakawa K., Nakata B., Fujihara T., Sawada T., Kato Y., et al. Expression of intercellular adhesion molecule-1 in invasive breast cancer reflects low growth potential, negative lymph node involvement, and good prognosis. Clin Cancer Res 1998, 4(1):31-36.
42. Liu N.Q., Dekker L.J., Stingl C., Güzel C., De Marchi T., Martens J.W., et al. Quantitative proteomic analysis of microdissected breast cancer tissues: comparison of label-free and SILAC-based quantification with shotgun, directed, and targeted MS approaches. J Proteome Res 2013, 12(10):4627-4641.
43. Didangelos A., Yin X., Mandal K., Saje A., Smith A., Xu Q., et al. Extracellular matrix composition and remodeling in human abdominal aortic aneurysms: a proteomics approach. Mol Cell Proteomics 2011, 10(8). [M111.008128].